Trial Profile
A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Hyperaldosteronism; Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 16 May 2014 New trial record